Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies

References

• SiegelRMaJZouZCancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• MohlerJLKantoffPWArmstrongAJProstate cancer, version 1. 2014J Natl Compr Canc Netw201311121471147924335682
   PubMed Web of Science ®Google Scholar
• CooksonMSRothBJDahmPCastration-resistant prostate cancer: AUA GuidelineJ Urol2013190242943823665272
   PubMed Web of Science ®Google Scholar
• MezynskiJPezaroCBianchiniDAntitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?Ann Oncol201223112943294722771826
   PubMed Web of Science ®Google Scholar
• NoonanKLNorthSBittingRLClinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamideAnn Oncol20132471802180723585511
   PubMed Web of Science ®Google Scholar
• PezaroCJOmlinAGAltavillaAActivity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine AgentsEur Urol2013
   Google Scholar
• MohlerJLKantoffPWArmstrongAJProstate cancer, version 2.2014J Natl Compr Canc Netw201412568671824812137
   PubMed Web of Science ®Google Scholar
• El-AmmJAragon-ChingJBThe changing landscape in the treatment of metastatic castration-resistant prostate cancerTher Adv Med Oncol201351254023323145
   PubMed Web of Science ®Google Scholar
• HugginsCHodgesCVStudies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostateCA Cancer J Clin19722242322404625049
   PubMedGoogle Scholar
• McLeodDGHormonal therapy: historical perspective to future directionsUrology2003612 Suppl 13712667881
   PubMed Web of Science ®Google Scholar
• HellerstedtBAPientaKJThe current state of hormonal therapy for prostate cancerCA Cancer J Clin200252315417912018929
   PubMed Web of Science ®Google Scholar
• SharifiNGulleyJLDahutWLAndrogen deprivation therapy for prostate cancerJAMA2005294223824416014598
   PubMed Web of Science ®Google Scholar
• MontgomeryRBMostaghelEAVessellaRMaintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthCancer Res200868114447445418519708
   PubMed Web of Science ®Google Scholar
• MohlerJLTitusMABaiSActivation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancerCancer Res20117141486149621303972
   PubMed Web of Science ®Google Scholar
• AuchusRJOverview of dehydroepiandrosterone biosynthesisSemin Reprod Med200422428128815635496
   PubMed Web of Science ®Google Scholar
• GoyalJAntonarakisESClinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate CancerClin Med Insights Urol20132013711424482578
   PubMedGoogle Scholar
• AttardGReidAHOlmosDAntitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone drivenCancer Res200969124937494019509232
   PubMed Web of Science ®Google Scholar
• AttardGReidAHA’HernRSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerJ Clin Oncol200927233742374819470933
   PubMed Web of Science ®Google Scholar
• PiaAVignaniFAttardGStrategies for managing ACTH dependent mineralocorticoid excess induced by abirateroneCancer Treat Rev201339896697323582279
   PubMed Web of Science ®Google Scholar
• AttardGReidAHYapTAPhase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenJ Clin Oncol200826284563457118645193
   PubMed Web of Science ®Google Scholar
• DanilaDCMorrisMJde BonoJSPhase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerJ Clin Oncol20102891496150120159814
   PubMed Web of Science ®Google Scholar
• ReidAHAttardGDanilaDCSignificant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateJ Clin Oncol20102891489149520159823
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMolinaAAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol2012131098399222995653
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• RathkopfDESmithMRde BonoJSUpdated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Eur Urol2014
   Google Scholar
• BostwickDGPacelliABluteMProstate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 casesCancer19988211225622619610707
   PubMed Web of Science ®Google Scholar
• GoldfarbDASteinBSShamszadehMPetersenORAge-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigenJ Urol19861366126612692430115
   PubMed Web of Science ®Google Scholar
• PatelPHKocklerDRSipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancerAnn Pharmacother2008421919818094343
   PubMed Web of Science ®Google Scholar
• SheikhNAPetrylakDKantoffPWSipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerCancer Immunol Immunother201362113714722865266
   PubMed Web of Science ®Google Scholar
• SmallEJFratesiPReeseDMImmunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cellsJ Clin Oncol200018233894390311099318
   PubMed Web of Science ®Google Scholar
• SmallEJSchellhammerPFHiganoCSPlacebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309416809734
   PubMed Web of Science ®Google Scholar
• HiganoCSSchellhammerPFSmallEJIntegrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCancer2009115163670367919536890
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• MitaACDenisLJRowinskyEKPhase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsClin Cancer Res200915272373019147780
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• PalSKTwardowskiPSartorOCritical appraisal of cabazitaxel in the management of advanced prostate cancerClin Interv Aging2010539540221152241
   PubMed Web of Science ®Google Scholar
• BahlAOudardSTombalBImpact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trialAnn Oncol20132492402240823723295
   PubMed Web of Science ®Google Scholar
• LewingtonVJMcEwanAJAckeryDMA prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to boneEur J Cancer19912789549581716935
   PubMed Web of Science ®Google Scholar
• LaingAHAckeryDMBaylyRJStrontium-89 chloride for pain palliation in prostatic skeletal malignancyBr J Radiol1991647658168221717094
   PubMed Web of Science ®Google Scholar
• SerafiniANHoustonSJRescheIPalliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trialJ Clin Oncol1998164157415819552068
   PubMed Web of Science ®Google Scholar
• SartorOReidRHHoskinPJSamarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancerUrology200463594094515134985
   PubMed Web of Science ®Google Scholar
• FinlayIGMasonMDShelleyMRadioisotopes for the palliation of metastatic bone cancer: a systematic reviewLancet Oncol20056639240015925817
   PubMed Web of Science ®Google Scholar
• GoyalJAntonarakisESBone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastasesCancer Lett2012323213514622521546
   PubMed Web of Science ®Google Scholar
• El-AmmJFreemanAPatelNAragon-ChingJBBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigmsProstate Cancer2013201321068624069538
   PubMedGoogle Scholar
• ParkerCNilssonSHeinrichDAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• BrulandOSNilssonSFisherDRHigh-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?Clin Cancer Res20061220 Pt 26250s6257s17062709
   PubMed Web of Science ®Google Scholar
• LiepeKAlpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancerCurr Opin Investig Drugs2009101213461358
   PubMedGoogle Scholar
• KerrC(223)Ra targets skeletal metastases and spares normal tissueLancet Oncol20023845312147423
   PubMed Web of Science ®Google Scholar
• NilssonSLarsenRHFossaSDFirst clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastasesClin Cancer Res200511124451445915958630
   PubMed Web of Science ®Google Scholar
• SartorOGillessenSTreatment sequencing in metastatic castrate-resistant prostate cancerAsian J Androl201416342643124675654
   PubMed Web of Science ®Google Scholar
• PistersLLTroncosoPZhauHEc-met proto-oncogene expression in benign and malignant human prostate tissuesJ Urol199515412932987539865
   PubMed Web of Science ®Google Scholar
• BorreMOffersenBVNerstromBOvergaardJMicrovessel density predicts survival in prostate cancer patients subjected to watchful waitingBr J Cancer19987879409449764587
   PubMed Web of Science ®Google Scholar
• SmithDCSmithMRSweeneyCCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialJ Clin Oncol201331441241923169517
   PubMed Web of Science ®Google Scholar
• LeeRJSaylorPJMichaelsonMDA dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastasesClin Cancer Res201319113088309423553848
   PubMed Web of Science ®Google Scholar
• IsaacsJTPiliRQianDZIdentification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancerProstate200666161768177816955399
   PubMed Web of Science ®Google Scholar
• IsaacsJTThe long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancerExpert Opin Investig Drugs2010191012351243
   PubMed Web of Science ®Google Scholar
• BrattOHaggmanMAhlgrenGOpen-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancerBr J Cancer200910181233124019755981
   PubMed Web of Science ®Google Scholar
• PiliRHaggmanMStadlerWMPhase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancerJ Clin Oncol201129304022402821931019
   PubMed Web of Science ®Google Scholar
• WeberJReview: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse eventsOncologist200712786487217673617
   PubMed Web of Science ®Google Scholar
• DrakeCKwonEFizaziKResults of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)J Clin Oncol201432Suppl 4 Abstr 2
   PubMedGoogle Scholar
• KwonEDDrakeCGScherHIIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialLancet Oncol201415770071224831977
   PubMed Web of Science ®Google Scholar
• NingYMPierceWMaherVEEnzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: US Food and Drug Administration drug approval summaryClin Cancer Res201319226067607324141628
   PubMed Web of Science ®Google Scholar
• LambADMassieCENealDEThe transcriptional programme of the androgen receptor (AR) in prostate cancerBJU Int2014113335836624053777
   PubMed Web of Science ®Google Scholar
• El-AmmJPatelNFreemanAAragon-ChingJBMetastatic castration-resistant prostate cancer: critical review of enzalutamideClin Med Insights Oncol2013723524524179414
   PubMedGoogle Scholar
• JungMEOukSYooDStructure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)J Med Chem20105372779279620218717
   PubMed Web of Science ®Google Scholar
• ScherHIBeerTMHiganoCSAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyLancet201037597241437144620398925
   PubMed Web of Science ®Google Scholar
• BennettLLIngasonAEnzalutamide (Xtandi) for patients with metastatic, resistant prostate cancerAnn Pharmacother201448453053724458946
   PubMed Web of Science ®Google Scholar
• Enzalutamide (Xtandi) [package insert]Northbrook, ILAstellas Pharma US2014
   Google Scholar
• ChenCDWelsbieDSTranCMolecular determinants of resistance to antiandrogen therapyNat Med2004101333914702632
   PubMed Web of Science ®Google Scholar
• KolvenbagGJFurrBJBlackledgeGRReceptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activityProstate Cancer Prostatic Dis19981630731412496872
   PubMed Web of Science ®Google Scholar
• FossaSDSleePHBrausiMFlutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary groupJ Clin Oncol2001191627111134196
   PubMed Web of Science ®Google Scholar
• AkazaHHinotsuSUsamiMCombined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survivalCancer2009115153437344519536889
   PubMed Web of Science ®Google Scholar
• CrawfordEDEisenbergerMAMcLeodDGA controlled trial of leuprolide with and without flutamide in prostatic carcinomaN Engl J Med198932174194242503724
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• Rodriguez-VidaABianchiniDVan HemelrijckMIs there an anti-androgen withdrawal syndrome with enzalutamide?BJU Int2014
   Web of Science ®Google Scholar
• HiganoCSBeerTMTaplinMEAntitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: long-term follow-up of a phase I/II studyJ Clin Oncol201129Supp 7 Abstr 134
   Web of Science ®Google Scholar
• ScherHIFizaziKSaadFIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• ScherHFizaziKSaadFAssociation of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 AFFIRM study of Enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI)Annals of Oncology201223Suppl 9 Abstr 899PD
   PubMedGoogle Scholar
• AroraVKSchenkeinEMuraliRGlucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockadeCell201315561309132224315100
   PubMed Web of Science ®Google Scholar
• BeerTMArmstrongAJSternbergCNEnzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL studyJ Clin Oncol201432Suppl 4LBA1
   Google Scholar
• BeerTMArmstrongAJRathkopfDEEnzalutamide in Metastatic Prostate Cancer before ChemotherapyN Engl J Med Epub612014
   Google Scholar
• van SoestRJvan RoyenMEde MorreeESCross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancerEur J Cancer201349183821383024200698
   PubMed Web of Science ®Google Scholar
• ChengHNadalRGulatiRThe effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPCJ Clin Oncol201432Suppl 4 Abstr 8
   Web of Science ®Google Scholar
• ChismDDDe SilvaDWhangYEMechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancerExpert Rev Anticancer Ther20141311024927631
   PubMedGoogle Scholar
• LiuCLouWZhuYNiclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerClin Cancer Res201420123198321024740322
   PubMed Web of Science ®Google Scholar
• SandaMGDunnRLMichalskiJQuality of life and satisfaction with outcome among prostate-cancer survivorsN Engl J Med2008358121250126118354103
   PubMed Web of Science ®Google Scholar
• HarlandSStaffurthJMolinaAEffect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapyEur J Cancer201349173648365723973186
   PubMed Web of Science ®Google Scholar
• MillerKScherHIFizaziKEffect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM studyASCO Meeting Abstracts2013316_Suppl17
   Google Scholar
• DreicerRJonesROudardSResults from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)J Clin Oncol2014324_Suppl Abstr 7
   Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar